Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Systematic Review of Published Case Studies

This systematic review of published case studies evaluates the potential risks of treating bipolar depression with psilocybin.

ABSTRACT

Objective: Given the treatment limitations of depression in bipolar disorder, we evaluated the known risks of using psilocybin (and similar substances). This includes a systematic assessment of published case histories, to assess the risk of psilocybin as a treatment of depression in bipolar disorder.
Data Sources: A comprehensive search of case studies published through December 31, 2020 was conducted using the following electronic databases: PubMed, Web of Science, and PsychInfo, focusing on classic psychedelics and case studies or case histories.
Study Selection: Our search terms resulted in 541 hits, of which 43 were non-duplicates of case studies with individuals having an adverse reaction to a psychedelic substance. Of those, 15 case studies indicated some form of adverse event involving mania or manic like behavior that persisted beyond the acute intoxication of the substance.
Data Extraction: Two independent evaluators assessed all possible cases, focusing on manic behavior based on DSM criteria. Two separate evaluators convened to evaluate cases where the case information was unclear.
Results: Of the 15 cases, four involved psilocybin, two cases involved individuals with a likely pre-existing diagnosis of bipolar disorder, and three involved individuals without a history of polysubstance abuse or concurrent polysubstance use.
Conclusions: We conclude that there is some evidence of risk of activating mania with these substances, but that the risk does not appear to be strong or overwhelming. Instead a careful prospective study, such as an open-label treatment protocol with careful controls, appears warranted in this population.

For more updates on the latest psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Psilocybin for Creativity: An Investigation

Next
Next

Ethical and legal issues in psychedelic harm reduction and integration therapy